EUVIMEDEUVIMED entdecken
Crossref

Whether to continue combining carbapenems to treat carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia in critically ill patients: a retrospective efficacy and safety analysis

Cheng Shiqi, Wang Chuhui, Zhang Yijing, Qiu Yulan, Chen Jiaojiao, Chen Keyu, Shi Qindong, Zeng Xiaoyan, Dong Yalin

European Journal of Clinical Microbiology & Infectious Diseases · 2025

DOI: 10.1007/s10096-025-05063-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2025. Verfasst von Cheng Shiqi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. Hauptthemen laut MEDLINE: Carbapenems, Acinetobacter baumannii, Acinetobacter Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Innovation Capability Support Program in Shaanxi province of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To explore the efficacy and safety of non-carbapenem-containing (NCC) regimens and carbapenem-containing regimens (CC) regimens, along with the factors influencing the outcomes in critically ill patients with carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia. This study retrospectively enrolled critically ill patients with CRAB pneumonia who were treated with NCC and CC regimens in a teaching hospital. The primary efficacy outcome was the 28-day clinical efficacy rate, and the safety outcome was the incidence of nephrotoxicity. After the propensity score matching analysis removed the differences between the two groups, the differences in outcomes were statistically analyzed. Cox regression and logistic regression models were used to analyze the factors influencing the outcomes of critically ill patients with CRAB pneumonia. Data from 168 critically ill patients with CRAB pneumonia were eventually included in this study for analysis (NCC = 84, CC = 84). The 28-day clinical efficacy rate was significantly lower in the CC group compared to the NCC group (40.5% vs. 57.1%, P = 0.031), and the incidence of nephrotoxicity was not significantly different in the two groups (P > 0.05). Logistic analysis showed that the prescription of carbapenems was the risk factor of decreased clinical efficacy (aOR = 0.494, 95%CI = 0.262-0.932, P = 0.029) and reduced microbiological eradication (aOR = 0.397, 95%CI = 0.201-0.783, P = 0.008) in patients. CC regimen may not contribute to the 28-day clinical efficacy of CRAB pneumonia and further studies are necessary to elucidate the CC regimen when treating CRAB pneumonia in critically ill patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarbapenemsAcinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial AgentsHealthcare-Associated PneumoniaCross InfectionHumansMaleFemaleRetrospective StudiesCritical IllnessMiddle AgedAgedTreatment OutcomeDrug Therapy, CombinationAged, 80 and overDrug Resistance, Multiple, BacterialAdult

Stichwörter der Autor:innen

Carbapenem-resistant Acinetobacter baumanniiCarbapenemsCombination therapy regimenNosocomial pneumonia

Substanzen

CarbapenemsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
  • Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
  • Department of Laboratory Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
  • Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. dongyalin@mail.xjtu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Innovation Capability Support Program in Shaanxi province of China

Zitieren

APA

Shiqi, C., Chuhui, W., Yijing, Z., Yulan, Q., Jiaojiao, C., Keyu, C., Qindong, S., Xiaoyan, Z., & Yalin, D. (2025). Whether to continue combining carbapenems to treat carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia in critically ill patients: a retrospective efficacy and safety analysis. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-025-05063-2

Vancouver

Shiqi C, Chuhui W, Yijing Z, Yulan Q, Jiaojiao C, Keyu C, et al. Whether to continue combining carbapenems to treat carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia in critically ill patients: a retrospective efficacy and safety analysis. European Journal of Clinical Microbiology & Infectious Diseases. 2025. doi:10.1007/s10096-025-05063-2

BibTeX
@article{Shiqi2025,
  author = {Shiqi, Cheng and Chuhui, Wang and Yijing, Zhang and Yulan, Qiu and Jiaojiao, Chen and Keyu, Chen and Qindong, Shi and Xiaoyan, Zeng and Yalin, Dong},
  title = {Whether to continue combining carbapenems to treat carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia in critically ill patients: a retrospective efficacy and safety analysis},
  journal = {European Journal of Clinical Microbiology & Infectious Diseases},
  year = {2025},
  doi = {10.1007/s10096-025-05063-2}
}
Kostenlos starten →